Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aura Biosciences Inc (AURA – Research Report), Iovance Biotherapeutics (IOVA – Research Report) and Intellia Therapeutics (NTLA – Research Report).
Aura Biosciences Inc (AURA)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Aura Biosciences Inc on May 9 and set a price target of $19.00. The company’s shares closed last Monday at $7.18, close to its 52-week low of $5.99.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
Currently, the analyst consensus on Aura Biosciences Inc is a Strong Buy with an average price target of $19.75, representing a 167.6% upside. In a report issued on May 9, BTIG also maintained a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
Iovance Biotherapeutics (IOVA)
Robert W. Baird analyst Colleen M. Kusy reiterated a Buy rating on Iovance Biotherapeutics on May 9 and set a price target of $26.00. The company’s shares closed last Monday at $10.88.
According to TipRanks.com, Kusy is ranked 0 out of 5 stars with an average return of
Iovance Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.64, a 128.7% upside from current levels. In a report issued on May 2, Barclays also maintained a Buy rating on the stock with a $22.00 price target.
Intellia Therapeutics (NTLA)
Robert W. Baird analyst Jack Allen maintained a Hold rating on Intellia Therapeutics on May 9 and set a price target of $24.00. The company’s shares closed last Monday at $25.42.
According to TipRanks.com, Allen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $62.79, which is a 151.1% upside from current levels. In a report issued on May 9, Citi also maintained a Hold rating on the stock with a $29.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AURA:
- Aura Biosciences reports Q1 EPS (40c), consensus (49c)
- Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
- Aura Biosciences to Participate in Upcoming Investor Conferences
- Raj Parekh to Exit Board at Aura Biosciences’ Meeting
- 3 Best Stocks to Buy Now, 3/29/2024, According to Top Analysts
